Linezolid update: Stable activity following more than a decade of clinical use and summary of associated resistance mechanisms

Linezolid, approved for clinical use since 2000, has become an important addition to the anti-Gram-positive infection armamentarium. This oxazolidinone drug has in vitro and in vivo activity against essentially all Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). The in vitro activity of linezolid was well documented prior to its clinical application, and several ongoing surveillance studies demonstrated consistent and potent results during the subsequent years of clinical use.

Source: Drug Resistance Updates - April 6, 2014 Category: Drugs & Pharmacology Authors: Rodrigo E. Mendes, Lalitagauri M. Deshpande, Ronald N. Jones Tags: Articles Source Type: research